Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations.

Schechter MS, VanDevanter DR, Pasta DJ, Short SA, Morgan WJ, Konstan MW; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Ann Am Thorac Soc. 2018 Feb;15(2):225-233. doi: 10.1513/AnnalsATS.201702-111OC.

PMID:
29140726
2.

Effects of CO2 and temperature on tritrophic interactions.

Dyer LA, Richards LA, Short SA, Dodson CD.

PLoS One. 2013 Apr 25;8(4):e62528. doi: 10.1371/journal.pone.0062528. Print 2013.

3.

The human ACC2 CT-domain C-terminus is required for full functionality and has a novel twist.

Madauss KP, Burkhart WA, Consler TG, Cowan DJ, Gottschalk WK, Miller AB, Short SA, Tran TB, Williams SP.

Acta Crystallogr D Biol Crystallogr. 2009 May;65(Pt 5):449-61. doi: 10.1107/S0907444909008014. Epub 2009 Apr 18.

4.

Chromatin condensation in terminally differentiating mouse erythroblasts does not involve special architectural proteins but depends on histone deacetylation.

Popova EY, Krauss SW, Short SA, Lee G, Villalobos J, Etzell J, Koury MJ, Ney PA, Chasis JA, Grigoryev SA.

Chromosome Res. 2009;17(1):47-64. doi: 10.1007/s10577-008-9005-y. Epub 2009 Jan 27.

5.

Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.

Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R, Freeman A, Ferris RG, Andrews CW, Boone L, Chan JH, Stammers DK.

J Med Chem. 2008 Aug 28;51(16):5000-8. doi: 10.1021/jm8004493. Epub 2008 Jul 30.

PMID:
18665583
6.

Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.

Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Chan JH, Kleim JP, Stammers DK.

J Med Chem. 2007 May 17;50(10):2301-9. Epub 2007 Apr 19.

PMID:
17441703
7.

A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.

Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, Short SA, Thompson SK, Stewart EL, Laping NJ, Williams SP, Bray JD.

Mol Endocrinol. 2007 May;21(5):1066-81. Epub 2007 Mar 13.

PMID:
17356170
8.

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.

Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK.

FEBS J. 2006 Aug;273(16):3850-60.

9.

Targeted gene deletion demonstrates that the cell adhesion molecule ICAM-4 is critical for erythroblastic island formation.

Lee G, Lo A, Short SA, Mankelow TJ, Spring F, Parsons SF, Yazdanbakhsh K, Mohandas N, Anstee DJ, Chasis JA.

Blood. 2006 Sep 15;108(6):2064-71. Epub 2006 May 11.

10.

Fox-2 splicing factor binds to a conserved intron motif to promote inclusion of protein 4.1R alternative exon 16.

Ponthier JL, Schluepen C, Chen W, Lersch RA, Gee SL, Hou VC, Lo AJ, Short SA, Chasis JA, Winkelmann JC, Conboy JG.

J Biol Chem. 2006 May 5;281(18):12468-74. Epub 2006 Mar 14.

11.

Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.

Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW 3rd, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR.

J Med Chem. 2006 Jan 26;49(2):727-39.

PMID:
16420058
12.

Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.

Hazen RJ, Harvey RJ, St Clair MH, Ferris RG, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Romines KR, Chan JH, Boone LR.

Antimicrob Agents Chemother. 2005 Nov;49(11):4465-73.

13.

Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.

Ferris RG, Hazen RJ, Roberts GB, St Clair MH, Chan JH, Romines KR, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Weaver KL, Selleseth DW, Moniri KR, Boone LR.

Antimicrob Agents Chemother. 2005 Oct;49(10):4046-51.

14.

Modelling the leaching of Pb, Cd, As, and Cr from cementitious waste using PHREEQC.

Halim CE, Short SA, Scott JA, Amal R, Low G.

J Hazard Mater. 2005 Oct 17;125(1-3):45-61.

PMID:
16043281
15.
16.

Evaluating the applicability of regulatory leaching tests for assessing the hazards of Pb-contaminated soils.

Halim CE, Scott JA, Amal R, Short SA, Beydoun D, Low G, Cattle J.

J Hazard Mater. 2005 Apr 11;120(1-3):101-11.

PMID:
15811670
17.

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.

Freeman GA, Andrews Iii CW 3rd, Hopkins AL, Lowell GS, Schaller LT, Cowan JR, Gonzales SS, Koszalka GW, Hazen RJ, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Reynolds DJ, Milton J, Ren J, Stuart DI, Stammers DK, Chan JH.

J Med Chem. 2004 Nov 18;47(24):5923-36.

PMID:
15537347
18.

Fourier transform ion cyclotron resonance MS reveals the presence of a water molecule in an enzyme transition-state analogue complex.

Borchers CH, Marquez VE, Schroeder GK, Short SA, Snider MJ, Speir JP, Wolfenden R.

Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15341-5. Epub 2004 Oct 19.

19.

Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes.

Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP.

J Med Chem. 2004 Jun 17;47(13):3381-7.

PMID:
15189034
20.

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.

Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers DK.

J Mol Biol. 2004 Feb 20;336(3):569-78.

PMID:
15095972
21.

Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell GS, Andrews CW 3rd, Reynolds DJ, St Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR.

J Med Chem. 2004 Feb 26;47(5):1175-82.

PMID:
14971897
22.

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Chan JH, Hong JS, Hunter RN 3rd, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews CW 3rd, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Ott RJ, Ren J, Hopkins A, Stuart DI, Stammers DK.

J Med Chem. 2001 Jun 7;44(12):1866-82.

PMID:
11384233
23.
24.
25.

Dissecting a charged network at the active site of orotidine-5'-phosphate decarboxylase.

Miller BG, Snider MJ, Wolfenden R, Short SA.

J Biol Chem. 2001 May 4;276(18):15174-6. Epub 2001 Jan 30.

26.

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.

Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK.

Structure. 2000 Oct 15;8(10):1089-94.

29.

Contribution of enzyme-phosphoribosyl contacts to catalysis by orotidine 5'-phosphate decarboxylase.

Miller BG, Snider MJ, Short SA, Wolfenden R.

Biochemistry. 2000 Jul 18;39(28):8113-8.

PMID:
10889016
30.

Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.

Ross L, Johnson M, Ferris RG, Short SA, Boone LR, Melby TE, Lanier R, Shaefer M, St Clair M.

J Hum Virol. 2000 May-Jun;3(3):144-9.

PMID:
10881994
31.

Crystallization of native and selenomethionyl yeast orotidine 5'-phosphate decarboxylase.

Miller BG, Hassell AM, Milburn MV, Short SA.

Acta Crystallogr D Biol Crystallogr. 2000 Apr;56(Pt 4):472-4.

PMID:
10739924
32.
33.

Activity of yeast orotidine-5'-phosphate decarboxylase in the absence of metals.

Miller BG, Smiley JA, Short SA, Wolfenden R.

J Biol Chem. 1999 Aug 20;274(34):23841-3.

34.

Product release is the major contributor to kcat for the hepatitis C virus helicase-catalyzed strand separation of short duplex DNA.

Porter DJ, Short SA, Hanlon MH, Preugschat F, Wilson JE, Willard DH Jr, Consler TG.

J Biol Chem. 1998 Jul 24;273(30):18906-14.

35.
36.
37.
39.

Active site amino acids that participate in the catalytic mechanism of nucleoside 2'-deoxyribosyltransferase.

Short SA, Armstrong SR, Ealick SE, Porter DJ.

J Biol Chem. 1996 Mar 1;271(9):4978-87.

40.

Cytidine deaminase complexed to 3-deazacytidine: a "valence buffer" in zinc enzyme catalysis.

Xiang S, Short SA, Wolfenden R, Carter CW Jr.

Biochemistry. 1996 Feb 6;35(5):1335-41.

PMID:
8634261
41.
42.

Synthesis and antiviral activity of 2'-deoxy-4'-thio purine nucleosides.

Van Draanen NA, Freeman GA, Short SA, Harvey R, Jansen R, Szczech G, Koszalka GW.

J Med Chem. 1996 Jan 19;39(2):538-42.

PMID:
8558524
43.
45.
46.

Transition-state selectivity for a single hydroxyl group during catalysis by cytidine deaminase.

Xiang S, Short SA, Wolfenden R, Carter CW Jr.

Biochemistry. 1995 Apr 11;34(14):4516-23.

PMID:
7718553
47.

Major contribution of a carboxymethyl group to transition-state stabilization by cytidine deaminase: mutation and rescue.

Carlow DC, Smith AA, Yang CC, Short SA, Wolfenden R.

Biochemistry. 1995 Apr 4;34(13):4220-4.

PMID:
7703234
48.

2-amino-9-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranosyl)-6-substituted-9H-purines: synthesis and anti-HIV activity.

Freeman GA, Shaver SR, Rideout JL, Short SA.

Bioorg Med Chem. 1995 Apr;3(4):447-58.

PMID:
8581428
49.

Mutations affecting transition-state stabilization by residues coordinating zinc at the active site of cytidine deaminase.

Smith AA, Carlow DC, Wolfenden R, Short SA.

Biochemistry. 1994 May 31;33(21):6468-74.

PMID:
8204580
50.

Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex.

Betts L, Xiang S, Short SA, Wolfenden R, Carter CW Jr.

J Mol Biol. 1994 Jan 14;235(2):635-56.

PMID:
8289286

Supplemental Content

Loading ...
Support Center